Get the Stockscreener App
2.10
1.87%
-0.04
Grace Therapeutics Inc stock is traded at $2.10, with a volume of 186.27K.
It is down -1.87% in the last 24 hours and down -3.67% over the past month.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
See More
Previous Close:
$2.14
Open:
$2.12
24h Volume:
186.27K
Relative Volume:
0.75
Market Cap:
$44.18M
Revenue:
-
Net Income/Loss:
$-7.79M
P/E Ratio:
-4.3732
EPS:
-0.4802
Net Cash Flow:
$-8.94M
1W Performance:
-0.94%
1M Performance:
-3.67%
6M Performance:
-45.74%
1Y Performance:
-31.37%
1-Day Range:
$2.08
$2.1899
1-Week Range:
$2.07
$2.20
52-Week Range:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
2.10 | 45.02M | 0 | -7.79M | -8.94M | -0.4802 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest ReadingTech Earnings Analysis - vinanet.vn
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares - Stock Titan
Major Investor Quietly Boosts Stake in Grace Therapeutics With Fresh Buy-In - TipRanks
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Announces Target Price $4 - Moomoo
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics, Inc. (NASDAQ: GRCE) Share Price, GRCE Stock News, GRCE Share Price & Updates - Kalkine
GRCE Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 74.42% EPS SurpriseManagement Guidance Update - vinanet.vn
Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Form 8K Grace Therapeutics, Inc For: 13 August By Investing.com - Investing.com Nigeria
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics posts investor deck on IV nimodipine candidate GTx-104 for aneurysmal subarachnoid hemorrhage - Bitget
Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise - Stock Titan
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers a 74.42% Surprise Despite No RevenueGuidance vs Actual - vinanet.vn
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock Titan
Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE - TradingView
GRCE Q2 2026 Earnings: 74.42% EPS Surprise as Loss Narrows to -$0.06SaaS Earnings Trends - vinanet.vn
Grace Therapeutics Raises Capital to Advance GTx-104 Program - TipRanks
Grace Therapeutics Raises $10 Million in Private Placement, Grants Registration Rights - TradingView
Grace Therapeutics announces securities purchase agreement for $10M private placement - ROI-NJ
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
GRCE Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Grace Therapeutics Secures $10M Private Placement Agreement - Intellectia AI
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
Grace Therapeutics raises $10 million in private placement By Investing.com - Investing.com Australia
Grace Therapeutics raises $10 million in private placement - Investing.com
Grace Therapeutics raises $10M in private place... - Pluang
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - Quiver Quantitative
Grace Therapeutics Announces $10 Million Private Placement - Moomoo
Grace Therapeutics prices USD 10 million private placement at USD 2.1 per share - Bitget
Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.com
GRCE Q2 2026 Earnings: 74.4% EPS Surprise Signals Stronger Cost DisciplineEarnings Per Share - vinanet.vn
GRCE Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Grace Therapeutics Receives Type a Meeting Minutes from FDA and Provides Update on GTx-104 Clinical-Stage Injectable Formulation - marketscreener.com
Grace Therapeutics (GRCE) FDA Meeting Highlights Manufacturing Compliance Focus, Market Implies High Growth - GuruFocus
Grace Therapeutics receives FDA meeting minutes on GTx-104 - Investing.com
Grace Therapeutics advances dual-source manufacturing for GTx-104 - TipRanks
Grace receives FDA Type A meeting minutes; advances dual-source manufacturing toward NDA resubmission - TradingView
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration - The Manila Times
Grace Therapeutics receives FDA meeting minutes on GTx-104 By Investing.com - Investing.com Canada
Grace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmission - Quiver Quantitative
Grace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104 - Stock Titan
Grace Therapeutics, Inc (GRCE) Institutional Confidence - TradingKey
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):